Bank of America hikes Eli Lilly price target on promising drug pipeline
Bank of America is standing by its bullish outlook on Eli Lilly . The bank reiterated its buy rating on the pharmaceutical stock. It also hiked its price target to $1,286 from $950, which points to 22% upside. Analyst Tim Anderson applauded Eli Lilly for maintaining its “first place” status in the large obesity and … Read more